Peroxisome proliferator-activated receptor γ-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells

Molecular Pharmacology

Volumn 67, Issue 4, 2005, Pages 1342-1348

  Huang, Jui Wen ^a   Shiau, Chung Wai ^a   Yang, Ya Ting ^a   Kulp, Samuel K ^a   Chen, Kuen Feng ^a   Brueggemeier, Robert W ^a   Shapiro, Charles L ^a   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BETA ACTIN; CIGLITAZONE; CYCLIN D1; ESTROGEN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TROGLITAZONE;

ARTICLE; BREAST CANCER; CELL GROWTH; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; WESTERN BLOTTING;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMANS; CYCLIN D1; DOWN-REGULATION; FEMALE; HUMANS; PPAR GAMMA; PROTEASOME ENDOPEPTIDASE COMPLEX; THIAZOLIDINEDIONES;

EID: 15744368845     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.007732     Document Type: Article

References (39)

1. Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, and Vigushin DM (2004) Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 10:8094-8104.
2. Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, and Pestell RG (1995) Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 270:23589-23597.
3. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, and Darnell JE Jr (1999) Stat3 as an oncogene. Cell 98:295-303.
4. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA, and Senderowicz AM (1999) Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59:4634-4641.
5. Choi YH, Lee SJ, Nguyen P, Jang JS, Lee J, Wu ML, Takano E, Maki M, Henkart PA, and Trepel JB (1997) Regulation of cyclin D1 by calpain protease. J Biol Chem 272:28479-28484.
6. Coqueret O (2002) Linking cyclins to transcriptional control. Gene 299:35-55.
7. D'Amico M, Hulit J, Amanatullah DF, Zafonte BT, Albanese C, Bouzahzah B, Fu M, Augenlicht LH, Donehower LA, Takemaru K, et al. (2000) The integrin-linked kinase regulates the cyclin D1 gene through glycogen synthase kinase 3β and cAMP-responsive element-binding protein-dependent pathways. J Biol Chem 275: 32649-32657.
8. Diehl JA, Cheng M, Roussel MF, and Sherr CJ (1998) Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12:3499-3511.
9. Diehl JA, Zindy F, and Sherr CJ (1997) Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11:957-972.
10. Germain D, Russell A, Thompson A, and Hendley J (2000) Ubiquitination of free cyclin D1 is independent of phosphorylation on threonine 286. J Biol Chem 275:12074-12079.
11. Henry DO, Moskalenko SA, Kaur KJ, Fu M, Pestell RG, Camonis JH, and White MA (2000) Ral GTPases contribute to regulation of cyclin D1 through activation of NF-kappaB. Mol Cell Biol 20:8084-8092.
12. Hui R, Finney GL, Carroll JS, Lee CS, Musgrove EA, and Sutherland RL (2002) Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells. Cancer Res 62:6916-6923.
13. Joyce D, Bouzahzah B, Fu M, Albanese C, D'Amico M, Steer J, Klein JU, Lee RJ, Segall JE, Westwick JK, et al. (1999) Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-κB- dependent pathway. J Biol Chem 274:25245-25249.
14. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL, and Robertson JF (1999) Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 5:2069-2076.
15. Lamb J, Ladha MH, McMahon C, Sutherland RL, and Ewen ME (2000) Regulation of the functional interaction between cyclin D1 and the estrogen receptor. Mol Cell Biol 20:8667-8675.
16. Langenfeld J, Kiyokawa H, Sekula D, Boyle J, and Dmitrovsky E (1997) Posttranslational regulation of cyclin D1 by retinoic acid: a chemoprevention mechanism. Proc Natl Acad Sci USA 94:12070-12074.
17. Lapillonne H, Konopleva M, Tsao T, Gold D, McQueen T, Sutherland RL, Madden T, and Andreeff M (2003) Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9- dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res 63: 5926-5939.
18. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK 3rd, Siegel PM, Hung MC, Yarden Y, et al. (2000) Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 20:672-683.
19. Lee RJ, Albanese C, Stenger RJ, Watanabe G, Inghirami G, Haines GK 3rd, Webster M, Muller WJ, Brugge JS, Davis RJ, and Pestell RG (1999) pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38 and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J Biol Chem 274:7341-7350.
20. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, et al. (2002) Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 41:6640-6650.
21. 1 checkpoint. Mol Cell Biol 16:6917-6925.
22. Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, Downward J, Pestell RG, and Kanakura Y (1999) Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO (Eur Mol Biol Organ) J 18:1367-1377.
23. McIntosh GG, Anderson JJ, Milton I, Steward M, Parr AH, Thomas MD, Henry JA, Angus B, Lennard TW, and Horne CH (1995) Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogens 11:885-891.
24. McMahon C, Suthiphongchai T, DiRenzo J, and Ewen ME (1999) P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci USA 96:5382-5387.
25. Kip1 association with cyclin E-Cdk2. J Biol Chem 276:47675-47683.
26. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW, Dowdy SF, Brown M, and Ewen ME (1997) Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17:5338-5347.
27. Prall OW, Rogan EM, Musgrove EA, Watts CK, and Sutherland RL (1998) c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol 18:4499-4508.
28. Qin C, Burghardt R, Smith R, Wormke M, Stewart J, and Safe S (2003) Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res 63:958-964.
29. Qin C, Morrow D, Stewart J, Spencer K, Porter W, Smith R 3rd, Phillips T, Abdelrahim M, Samudio I, and Safe S (2004) A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes. Mol Cancer Ther 3:247-260.
30. Seargent JM, Yates EA, and Gill JH (2004) GW9662, a potent antagonist of PPAR-gamma, inhibits growth of breast tumor cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br J Pharmacol 143:933-937.
31. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, and Ben-Ze'ev A (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96:5522-5527.
32. Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson NO, and Landberg G (2004) Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 90:1942-1948.
33. Wang C, Fu M, D'Amico M, Albanese C, Zhou JN, Brownlee M, Lisanti MP, Chatterjee VK, Lazar MA, and Pestell RG (2001) Inhibition of cellular proliferation through IkappaB kinase-independent and peroxisome proliferator-activated receptor gamma-dependent repression of cyclin D1. Mol Cell Biol 21:3057-3070.
34. Westwick JK, Lambert QT, Clark GJ, Symons M, Van Aelst L, Pestell RG, and Der CJ (1997) Rac regulation of transformation, gene expression and actin organization by multiple, PAK-independent pathways. Mol Cell Biol 17:1324-1335.
35. Wilcken NR, Prall OW, Musgrove EA, and Sutherland RL (1997) Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res 3:849-854.
36. Wu K, Wang C, D'Amico M, Lee RJ, Albanese C, Pestell RG, and Mani S (2002) Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther 1:695-706.
37. 1 cell cycle regulators. Biochem Biophys Res Commun 286:916-922.
38. Yu Q, Geng Y, and Sicinski P (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature (Lond) 411:1017-1021.
39. Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, and Michalides RJ (1997) CDK-independent activation of estrogen receptor by cyclin D1. Cell 88:405-415.